A managing partner at Baum Hedlund Aristei & Goldman in Los Angeles, California, attorney Michael Lin Baum has received multiple awards for his legal work. In 2019, the National Trial Lawyers Top 100 recognized Michael and his team as the Trial Team of the Year in the Mass Torts category. Recently, Michael Lin Baum’s team has filed a lawsuit alleging that the heartburn medication Zantac contains a chemical that causes cancer.
Also known as ranitidine hydrochloride, Zantac is prescribed not only as a remedy for stomach acid but also for gastric reflux, heartburn, and other gastrointestinal and throat problems. Since the 1980s, research has shown that one ingredient – N-Nitrosodimethylamine (NDMA) – may be carcinogenic.
In September 2019, the Food and Drug Administration said it was investigating the possibility that a 150 mg dose of Zantac exposes patients to 3,000 times the recommended daily dosage of NDMA. The lawsuit seeks damages for two plaintiffs in California and Pennsylvania. Defending the charges are five manufacturers: Boehringer Ingelheim, Sanofi, Chattem, Pfizer, and GlaxoSmithKline.